Pharmaceuticals

Blood Based Biomarkers Market Research: Growth Projections and Trends 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the blood based biomarkers market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Blood Based Biomarkers Market expected to reach by 2030?

The market for blood based biomarkers has expanded significantly in recent years. Its valuation is anticipated to rise from $25.83 billion in 2025 to $28.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. This historical growth can be attributed to advancements in molecular diagnostics, cancer screening programs, biomarker validation studies, improvements in hospital diagnostic infrastructure, and increased research funding.

The market for blood based biomarkers is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a valuation of $45.5 billion, demonstrating a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth during the projected period encompass the broadening of liquid biopsy applications, the rise of AI-powered biomarker analytics, increased demand for chronic disease monitoring, wider adoption of personalized medicine, and the proliferation of point-of-care testing. Significant developments expected during this timeframe involve an increasing embrace of non-invasive diagnostics, the extension of precision oncology uses, greater application in early disease discovery, a heightened need for tailored treatment oversight, and the incorporation into clinical decision support systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

What Drivers Are Driving Adoption Within The Blood Based Biomarkers Market?

The increasing incidence of cardiovascular diseases is projected to drive the expansion of the blood-based biomarkers market in the future. These diseases encompass various conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The surge in cardiovascular ailments primarily stems from escalating risk factors like inadequate diet and growing obesity levels. Blood-based biomarkers assist in the diagnosis and ongoing monitoring of cardiovascular diseases by offering valuable information on disease advancement, risk evaluation, and effectiveness of treatment via detectable substances within the blood. For example, in September 2024, a global health research initiative report by the US-based government agency, National Center for Biotechnology Information, projected a 90% increase in cardiovascular disease prevalence from 2025 to 2050, alongside an anticipated 35.6 million cardiovascular deaths by 2050. Consequently, the rising number of cardiovascular disease cases is fueling the expansion of blood-based biomarkers.

How Is The Blood Based Biomarkers Market Organized Into Various Segments?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

Which Trends Are Guiding The Evolution Of The Blood Based Biomarkers Market?

Leading companies within the blood-based biomarkers market are emphasizing technological advancements, such as high-accuracy blood biomarker tests, to support physicians in diagnosing Alzheimer’s disease. This type of test serves as a diagnostic instrument, utilizing specific biomarkers in the blood to identify diseases or monitor health conditions with a high degree of precision and reliability. For instance, in October 2023, Quanterix, a US-based life sciences company, introduced LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to assist physicians in diagnosing Alzheimer’s disease (AD) in adults with cognitive impairment. This test quantifies phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker significantly linked to AD pathology, particularly amyloid accumulation in the brain. The LucentAD p-Tau 217 test exhibits over 90% accuracy, conforming to strict diagnostic criteria, and is intended for use alongside other diagnostic tools rather than as a standalone option.

Who Are The Core Companies Influencing Trends In The Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Regions Are Projected To Dominate The Blood Based Biomarkers Market In The Coming Years?

North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Blood Based Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2026, By The Business Research Company

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795